If participant has previously received ibrutinib, ACP-196, ACP-319, or BGB-3311, participant will be in Group 1. Group 1 participants will receive treatment based on the results of the xenograft model. Participant and the doctor will decide participant's treatment based on this information. Participant's treatment will either be standard of care or participant will participate on another clinical research study.